All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub spoke to Uday Popat, MD Anderson Cancer Center, Houston, US, who discussed how he would manage a mildly symptomatic middle-aged woman with INT-1 primary myelofibrosis.
How would you manage a mildly symptomatic middle-aged woman with INT-1 primary myelofibrosis?
One of the major questions in this setting is whether or not to carry out HCT, and here Uday Popat outlines the key decision-making criteria.
Subscribe to get the best content related to MPN delivered to your inbox